USFD) on Thursday reported third-quarter profit of $148 million. On a per-share basis, the Rosemont, Illinois-based company said it had net income of 61 cents. Earnings, adjusted for non-recurring ...

Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M ...